作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
摘要: 自新型冠状病毒肺炎(coronavirus disease 2019, COVID-19)疫情暴发以来, 出现了若干COVID-19相关甲状腺疾病的报道, 包括亚急性甲状腺炎、自身免疫性甲状腺疾病、非甲状腺疾病综合征以及原因未明的甲状腺功能异常。本综述旨在对COVID-19相关甲状腺疾病的临床特点进行总结, 并探究可能的发生机制。Abstract: Since the outbreak of coronavirus disease 2019 (COVID-19), a number of COVID-19 related thyroid disorders have been reported, including subacute thyroiditis, autoimmune thyroid disease, non-thyroidal illness syndrome and some unexplained thyroid dysfunction. This review aimed to summarize clinical characteristics of COVID-19 related thyroid disorders and to discuss some possible mechanisms.作者贡献：李乃适、连小兰负责构思论文；陈紫晗负责查阅文献资料和撰写论文；李乃适、连小兰、陈紫晗负责修订论文。利益冲突：所有作者均声明不存在利益冲突
-
表 1 COVID-19伴发GD的病例特点
病例 年龄
(岁)性别 前驱时间
(周)*既往GD病史 TSH FT3 FT4 TRAb TPOAb 甲状腺放射性碘摄取率 治疗 参考文献 病例1 21 女 2 无 ↓ ↑ ↑ + NR NR MMI+β-RB Harris等[13] 病例2 45 女 8 有，已恢复正常2年 ↓ NR ↑ + NR NR MMI Jiménez-Blanco等[14] 病例3 61 女 4 有，已恢复正常4年 ↓ NR ↑ + NR ↑ MMI Jiménez-Blanco等[14] 病例4 60 女 5 有，已恢复正常35年 ↓ ↑ 正常范围 + + ↑ MMI+β-RB Mateu-Salat等[15] 病例5 53 女 9 无 ↓ ↑ ↑ + + ↑ MMI+β-RB Mateu-Salat等[15] *发现SARS-CoV-2感染至确诊GD的时间；NR：文献中未提及；COVID-19：新型冠状病毒肺炎；GD：Graves病；TSH：促甲状腺激素；FT3：游离三碘甲状腺原氨酸；FT4：游离甲状腺素；TRAb：促甲状腺激素受体抗体；TPOAb：抗甲状腺过氧化物酶抗体; MMI: 甲巯咪唑；β-RB：β受体阻滞剂 
下载: 导出CSV
-
[1] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8: 475-481. doi: 10.1016/S2213-2600(20)30079-5 [2] Ge H, Wang X, Yuan X, et al. The epidemiology and clinical information about COVID-19[J]. Eur J Clin Microbiol Infect Dis, 2020, 39: 1011-1019. doi: 10.1007/s10096-020-03874-z [3] Doustmohammadian S, Doustmohammadian A, Momeni M. Association between thyroid disorders and COVID-19: a protocol for a systematic review and meta-analysis[J]. Thyroid Res, 2021, 14: 21. doi: 10.1186/s13044-021-00113-1 [4] Pearce EN, Farwell AP, Braverman LE. Thyroiditis[J]. N Engl J Med, 2003, 348: 2646-2655. doi: 10.1056/NEJMra021194 [5] Desailloud R, Hober D. Viruses and thyroiditis: an update[J]. Virol J, 2009, 6: 5. doi: 10.1186/1743-422X-6-5 [6] Brancatella A, Ricci D, Viola N, et al. Subacute Thyroiditis After SARS-CoV-2 Infection[J]. J Clin Endocrinol Metab, 2020, 105: dgaa276. doi: 10.1210/clinem/dgz049 [7] Caron P. Thyroiditis and SARS-CoV-2 pandemic: a review[J]. Endocrine, 2021, 72: 326-331. doi: 10.1007/s12020-021-02689-y [8] Inaba H, Aizawa T. Coronavirus Disease 2019 and the Thyroid-Progress and Perspectives[J]. Front Endocrinol(Lausanne), 2021, 12: 708333. doi: 10.3389/fendo.2021.708333 [9] Ippolito S, Dentali F, Tanda ML. SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report[J]. J Endocrinol Invest, 2020, 43: 1171-1172. doi: 10.1007/s40618-020-01312-7 [10] Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19[J]. Nat Rev Rheumatol, 2020, 16: 413-414. doi: 10.1038/s41584-020-0448-7 [11] Testa A, Castaldi P, Fant V, et al. Prevalence of HCV Antibodies in Autoimmune Thyroid Disease[J]. Eur Rev Med Pharmacol Sci, 2006, 10: 183-186. [12] Sultanova A, Cistjakovs M, Gravelsina S, et al. Association of Active Human Herpesvirus-6 (HHV-6) Infection With Autoimmune Thyroid Gland Diseases[J]. Clin Microbiol Infect, 2017, 23: 50 e51-50 e55. [13] Harris A, Al Mushref M. Graves' Thyrotoxicosis Following SARS-CoV-2 Infection[J]. AACE Clin Case Rep, 2021, 7: 14-16. doi: 10.1016/j.aace.2020.12.005 [14] Jiménez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: a cause of recurrent Graves' hyperthyroidism? [J]. J Endocrinol Invest, 2021, 44: 387-388. doi: 10.1007/s40618-020-01440-0 [15] Mateu-Salat M, Urgell E, Chico A. SARS-CoV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19[J]. J Endocrinol Invest, 2020, 43: 1527-1528. doi: 10.1007/s40618-020-01366-7 [16] Tee LY, Hajanto S, Rosario BH. COVID-19 Complicated by Hashimoto's Thyroiditis[J]. Singapore Med J, 2021, 62: 265. doi: 10.11622/smedj.2020106 [17] Fliers E, Boelen A. An update on non-thyroidal illness syndrome[J]. J Endocrinol Invest, 2021, 44: 1597-1607. doi: 10.1007/s40618-020-01482-4 [18] Zou R, Wu C, Zhang S, et al. Euthyroid Sick Syndrome in Patients With COVID-19[J]. Front Endocrinol (Lausanne), 2020, 11: 566439. doi: 10.3389/fendo.2020.566439 [19] Khoo B, Tan T, Clarke SA, et al. Thyroid Function Before, During, and After COVID-19[J]. J Clin Endocrinol Metab, 2021, 106: e803-e811. doi: 10.1210/clinem/dgaa830 [20] Shabana TS, Anis SG, Ibrahim DM. Association between Thyroid Dysfunction and Intensive Care Unit-Acquired Weakness: A Case-Control Study[J]. Crit Care Res Pract, 2021, 2021: 8889036. [21] Wang W, Su X, Ding Y, et al. Thyroid function abnormalities in COVID-19 patients[J]. Front Endocrinol (Lausanne), 2020, 11: 623792. [22] Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with COVID-19: a retrospective study[J]. Thyroid, 2020, 31: 8-11. [23] Lania A, Sandri MT, Cellini M, et al. Thyrotoxicosis in patients with COVID-19: the Thyrcov study[J]. Eur J Endocrinol, 2020, 183: 381-387. doi: 10.1530/EJE-20-0335 [24] Gao W, Guo W, Guo Y, et al. Thyroid hormone concentrations in severely or critically ill patients with COVID-19[J]. J Endocrinol Invest, 2021, 44: 1031-1040. doi: 10.1007/s40618-020-01460-w [25] Campi I, Bulgarelli I, Dubini A, et al. The spectrum of thyroid function tests during hospitalization for SARS-CoV-2 infection[J]. Eur J Endocrinol, 2021, 184: 699-709. doi: 10.1530/EJE-20-1391 [26] Güven M, Gültekin H. The prognostic impact of thyroid disorders on the clinical severity of COVID-19: results of single-centre pandemic hospital[J]. Int J Clin Pract, 2021, 75: e14129. [27] Daraei M, Hasibi M, Abdollahi H, et al. Possible role of hypothyroidism in the prognosis of COVID-19[J]. Intern Med J, 2020, 50: 1410-1412. doi: 10.1111/imj.15000 [28] Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis[J]. Lancet Diabetes Endocrinol, 2020, 8: 739-741. doi: 10.1016/S2213-8587(20)30266-7 [29] Lam SD, Bordin N, Waman VP, et al. SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals[J]. Sci Rep, 2020, 10: 16471. doi: 10.1038/s41598-020-71936-5 [30] Li MY, Li L, Zhang Y, et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues[J]. Infect Dis Poverty, 2020, 9: 45. doi: 10.1186/s40249-020-00662-x [31] Rotondi M, Coperchini F, Ricci G, et al. Detection of SARS-CoV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis[J]. J Endocrinol Invest, 2021, 44: 1085-1090. doi: 10.1007/s40618-020-01436-w [32] Moore JB, June CH. Cytokine release syndrome in severe COVID-19[J]. Science, 2020, 368: 473-474. doi: 10.1126/science.abb8925 [33] Turner AJ, Tipnis SR, Guy JL, et al. Aceh/Ace2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ace inhibitors[J]. Can J Physiol Pharmacol, 2002, 80: 346-353. doi: 10.1139/y02-021 [34] Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2[J]. Antiviral Res, 2020, 177: 104759. doi: 10.1016/j.antiviral.2020.104759 [35] Luan J, Lu Y, Gao S, et al. A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2[J]. J Infect, 2020, 81: 318-356. [36] Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19[J]. Nat Immunol, 2020, 21: 1336-1345. doi: 10.1038/s41590-020-0782-6 [37] Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis[J]. Rev Med Virol, 2020, 30: 1-9. [38] Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19[J]. Nature, 2020, 583: 437-440. doi: 10.1038/s41586-020-2355-0 [39] Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type Ⅰ interferons in development of severe COVID-19[J]. Sci Immunol, 2020, 5: eabd1554. doi: 10.1126/sciimmunol.abd1554 [40] Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19[J]. Nature, 2020, 584: 463-469. doi: 10.1038/s41586-020-2588-y [41] Melo Silva Junior ML, Souza LMA, Dutra R, et al. Review on therapeutic targets for COVID-19: insights from cytokine storm[J]. Postgrad Med J, 2021, 97: 391-398. doi: 10.1136/postgradmedj-2020-138791 [42] Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection[J]. Diabetes Metab Syndr, 2020, 14: 1429-1430. doi: 10.1016/j.dsx.2020.07.044 [43] Caron P. Thyroid disorders and SARS-CoV-2 infection: from pathophysiological mechanism to patient management[J]. Ann Endocrinol (Paris), 2020, 81: 507-510. doi: 10.1016/j.ando.2020.09.001 [44] Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves' disease[J]. Immunol Res, 2012, 54: 191-203. doi: 10.1007/s12026-012-8312-8 [45] Kawashima A, Yamazaki K, Hara T, et al. Demonstration of innate immune responses in the thyroid gland: potential to sense danger and a possible trigger for autoimmune reactions[J]. Thyroid, 2013, 23: 477-487. doi: 10.1089/thy.2011.0480 [46] Lisco G, De Tullio A, Jirillo E, et al. Thyroid and COVID-19: a review on pathophysiological, clinical and organiza-tional aspects[J]. J Endocrinol Invest, 2021, 44: 1801-1814. doi: 10.1007/s40618-021-01554-z -
点击查看大图
表(1)
计量
- 文章访问数: 168
- HTML全文浏览量: 9
- PDF下载量: 36
- 被引次数: 0
